Clinical Trial

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2025-12-19
Trial Details
NCT Number NCT07108270
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms, Endometrial
Enrollment 30 participants
Start Date 2025-11-27
Primary Completion 2030-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-22